Elsevier

The Lancet

Volume 336, Issue 8712, 18 August 1990, Pages 392-395
The Lancet

Enhancement of recovery from psychiatric illness by methylfolate

https://doi.org/10.1016/0140-6736(90)91942-4Get rights and content

Abstract

41 (33%) of 123 patients with acute psychiatric disorders (DSM III diagnosis of major depression or schizophrenia) had borderline or definite folate deficiency (red-cell folate below 200 μg/l) and took part in a double-blind, placebo-controlled trial of methylfolate, 15 mg daily, for 6 months in addition to standard psychotropic treatment. Among both depressed and schizophrenic patients methylfolate significantly improved clinical and social recovery. The differences in outcome scores between methylfolate and placebo groups became greater with time. These findings add to the evidence implicating disturbances of methylation in the nervous system in the biology of some forms of mental illness.

References (29)

  • Mwp. Carney

    Serum folate values in 423 psychiatric patients

    Br Med J

    (1967)
  • Eh Reynolds et al.

    Folate metabolism in epileptic and psychiatric patients

    J Neurol Neurosurg Psychiatry

    (1971)
  • J. Edeh et al.

    Antiepileptic therapy, folate deficiency and psychiatric morbidity: results of a survey in general practice

    Epilepsia

    (1985)
  • H. Osmond et al.

    Schizophrenia: a new approach

    J Ment Sci

    (1952)
  • Cited by (343)

    View all citing articles on Scopus
    View full text